Astria Therapeutics
ATXS
ATXS was delisted on the 22nd of January, 2026.
50 hedge funds and large institutions have $51.5M invested in Astria Therapeutics in 2020 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 11 increasing their positions, 5 reducing their positions, and 4 closing their positions.
2,421% more call options, than puts
Call options by funds: $7.71M | Put options by funds: $306K
575% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 4
120% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 5
107% more capital invested
Capital invested by funds: $24.9M → $51.5M (+$26.6M)
85% more funds holding
Funds holding: 27 → 50 (+23)
1.85% more ownership
Funds ownership: 5.6% → 7.45% (+1.9%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$5.17M |
| 2 |
State Street
Boston,
Massachusetts
|
+$1.2M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$735K |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
+$643K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$458K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$184K |
| 2 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$148K |
| 3 |
JP Morgan Chase
New York
|
-$38K |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$35.9K |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$24K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
O
51
OrbiMed
New York
| – | -$184K | -7,400 | Closed |
|
|
52
Alyeska Investment Group
Chicago,
Illinois
| – | -$35.9K | -1,007 | Closed |
|
|
53
Victory Capital Management
San Antonio,
Texas
| – | -$24K | -992 | Closed |
|
|
KFI
54
Key Financial Inc
West Chester,
Pennsylvania
| – | -$2K | -67 | Closed |
|
ATXS Hedge Fund Activity: Q2 2020 in Review
50 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q2 2020, worth a combined $51.5M — up 107% from $24.9M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new ATXS positions and 4 closed out — a net gain of 23 holders — while 11 added to existing stakes and 5 trimmed.
The largest buyer was BlackRock, adding an estimated $5.17M. The largest seller was OrbiMed, exiting entirely with an estimated $184K sold.
- 50 institutional investors held Astria Therapeutics (ATXS) as of Q2 2020, up from 27 in Q1 2020.
- Funds reported $51.5M of Astria Therapeutics stock for Q2 2020, up 107% quarter-over-quarter.
- 27 funds opened new Astria Therapeutics positions in Q2 2020 and 4 closed out, a net change of +23 holders.
- The largest Astria Therapeutics buyer in Q2 2020 was BlackRock, an estimated $5.17M added.
- The largest Astria Therapeutics seller in Q2 2020 was OrbiMed, an estimated $184K sold.
Based on aggregated 13F filings for Q2 2020.